We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Assertio (ASRT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Assertio is one of 1158 individual stocks in the Medical sector. Collectively, these companies sit at #12 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Assertio is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ASRT's full-year earnings has moved 75% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ASRT has returned 19.3% so far this year. Meanwhile, the Medical sector has returned an average of -5.7% on a year-to-date basis. As we can see, Assertio is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Sensus Healthcare, Inc. (SRTS - Free Report) . The stock has returned 58.6% year-to-date.
In Sensus Healthcare, Inc.'s case, the consensus EPS estimate for the current year increased 15.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Assertio belongs to the Medical - Drugs industry, a group that includes 229 individual companies and currently sits at #163 in the Zacks Industry Rank. On average, stocks in this group have lost 13.7% this year, meaning that ASRT is performing better in terms of year-to-date returns.
On the other hand, Sensus Healthcare, Inc. belongs to the Medical - Instruments industry. This 102-stock industry is currently ranked #173. The industry has moved -14.1% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Assertio and Sensus Healthcare, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Assertio (ASRT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Assertio is one of 1158 individual stocks in the Medical sector. Collectively, these companies sit at #12 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Assertio is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ASRT's full-year earnings has moved 75% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ASRT has returned 19.3% so far this year. Meanwhile, the Medical sector has returned an average of -5.7% on a year-to-date basis. As we can see, Assertio is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Sensus Healthcare, Inc. (SRTS - Free Report) . The stock has returned 58.6% year-to-date.
In Sensus Healthcare, Inc.'s case, the consensus EPS estimate for the current year increased 15.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Assertio belongs to the Medical - Drugs industry, a group that includes 229 individual companies and currently sits at #163 in the Zacks Industry Rank. On average, stocks in this group have lost 13.7% this year, meaning that ASRT is performing better in terms of year-to-date returns.
On the other hand, Sensus Healthcare, Inc. belongs to the Medical - Instruments industry. This 102-stock industry is currently ranked #173. The industry has moved -14.1% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Assertio and Sensus Healthcare, Inc. as they could maintain their solid performance.